<?xml version="1.0" encoding="UTF-8"?>
<p id="Par8">The co-primary endpoints were: (1) the proportion of patients achieving the target collection of ≥5 × 10
 <sup>6</sup> CD34
 <sup>+</sup> cells/kg in ≤4 days of apheresis, and (2) total systemic exposure to plerixafor.
</p>
